Kestra Medical (KMTS) Technologies announced a strategic collaboration with Biobeat Technologies to expand diagnostic insight for patients prescribed the ASSURE Wearable Cardioverter Defibrillator. The agreement is anchored by an exclusive license and co-development arrangement and includes a $5M equity investment in Biobeat’s recently announced Series B financing. Biobeat has developed the only clinically validated, FDA-cleared cuffless, patch-worn ambulatory blood pressure monitoring device, leveraging photoplethysmography-based sensing to deliver continuous, noninvasive blood pressure measurement over a 24-hour period for hypertension diagnosis and management in the outpatient cardiac recovery setting. Kestra intends to integrate Biobeat’s technology into its product portfolio to make ABPM data available for patients prescribed the ASSURE WCD.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- Kestra Medical price target raised to $27 from $25 at Goldman Sachs
- Kestra Medical price target raised to $25 from $22 at Goldman Sachs
- Kestra Medical Technologies Reports Strong Earnings Growth
- Kestra Medical price target raised to $30 from $28 at Stifel
- Morning Movers: Cannabis stocks higher after reports of reclassification